Acquisition by Bell John Irving of 14534 shares of Immunocore Holdings at 50.47 subject to Rule 16b-3
| IMCR Stock | USD 29.60 0.14 0.47% |
Slightly above 61% of Immunocore Holdings' investor base is looking to short. The analysis of the overall investor sentiment regarding Immunocore Holdings suggests that many traders are alarmed. Immunocore Holdings' investing sentiment overview a quick insight into current market opportunities from investing in Immunocore Holdings. Many technical investors use Immunocore Holdings stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Immunocore |
Filed transaction by Immunocore Holdings Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Immunocore Holdings Fundamental Analysis
We analyze Immunocore Holdings' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunocore Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunocore Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Immunocore Holdings is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Immunocore Holdings Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immunocore Holdings stock to make a market-neutral strategy. Peer analysis of Immunocore Holdings could also be used in its relative valuation, which is a method of valuing Immunocore Holdings by comparing valuation metrics with similar companies.
Peers
Immunocore Holdings Related Equities
| LYRA | Lyra Therapeutics | 5.00 | ||||
| DSGN | Design Therapeutics | 2.77 | ||||
| KALV | Kalvista Pharmaceuticals | 2.41 | ||||
| ACLX | Arcellx | 2.39 | ||||
| LRMR | Larimar Therapeutics | 2.14 | ||||
| VTYX | Ventyx Biosciences | 1.79 | ||||
| GLUE | Monte Rosa | 0.89 | ||||
| PCVX | Vaxcyte | 0.19 | ||||
| MIRM | Mirum Pharmaceuticals | 1.30 | ||||
| VRDN | Viridian Therapeutics | 3.64 | ||||
| ERAS | Erasca | 3.68 | ||||
| NUVL | Nuvalent | 3.73 |
Additional Tools for Immunocore Stock Analysis
When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.